Antibodies and Biologics
Therapeutic antibodies have become one of the fastest growing drugs over recent years and a large number of patent applications are filed in this area. Other biological products, such as ligand traps, siRNA for gene silencing, aptamers, chimeric antigen receptors (CARs) and T cell receptors (TCRs) are also at the forefront of biomedical research. J A Kemp LLP is highly active in this field and we advise on all areas relating to these innovative therapeutic products, as well as in complementary fields such as immunology and immunotherapy.
Our expertise with antibodies includes not only “traditional” formats, but also alternative formats such as domain antibodies, BiTEs and other bispecific molecules. We are experienced in drafting antibody/biologic applications, prosecuting such applications at the EPO, managing global series of cases, portfolio building (for example covering new medical uses, formulations and combinations) and freedom to operate . We are also highly experienced in attacking and defending such patents in EPO Oppositions and Appeals and have expertise in obtaining Supplementary Protection Certificates (SPCs) for biologics. Our clients in this area range from major corporates to SMEs and universities.